Paris, Could 07, 2020, 7pm
AB Science is internet hosting stay webcast on Monday Could 11, 2020 on masitinib
together with isoquercetine for the remedy of COVID-19
AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a stay webcast on Monday 11, 2020 following the current authorization by the French Drugs Company, ANSM, to provoke a Section 2 examine evaluating masitinib together with isoquercetin for the remedy of COVID-19.
This examine (AB20001) is a randomized (1:1), open-label Section 2 scientific trial to guage the security and efficacy of masitinib mixed with isoquercetin in hospitalized sufferers with average and extreme COVID-19. The examine will enroll 200 sufferers (age ≥18 with out an higher age restrict) at medical facilities in France and different nations. The first goal is to enhance the scientific standing of sufferers after 15 days of remedy.
This webcast will characteristic a presentation by AB Science’s administration workforce and Jean-Pierre Kinet, Co-President of AB Science Scientific Committee and can current the detailed examine design and additional clarify the scientific rationale for combining masitinib with isoquercetin.
Dial-In & Webcast Info
Webcast date: Monday, Could 11, 2020. USA: 11:30am EST; Europe 5:30pm CET
Quantity for the US: +1 646 722 4916
Quantity for France: +33 1 72 72 74 03
Worldwide numbers (exterior US and France): Numbers for different nations are listed on the webcast web page
Convention ID: 77816444#
Jean-Pierre Kinet biography
Professor Jean-Pierre Kinet, M.D., is among the most distinguished immunology consultants worldwide, most well-known for locating a number of the genes and proteins constituting the immunoglobulin E receptor. These scientific breakthroughs contributed to the introduction of recent diagnostic instruments and therapies for illnesses associated to immune system dysregulation. He is also the co-founder and founding father of two biotech firms (AB Science and Astarix), and is a board member of a number of different biotech firms in Europe.
He’s Professor of Pathology at Harvard Medical Faculty (Boston – USA). He’s additionally a member of Nationwide Institute of Well being (NIH) professional panels, and of the medical Board of the American Bronchial asthma Basis within the USA. Jean-Pierre Kinet is a member of the Scientific Advisory Board of UCB Pharma and Managing Accomplice of iXLife Capital. Jean-Pierre Kinet acquired his medical diploma from the College of Liege (Belgium), and was skilled in inside medication on the Liège College hospital. He has written over 200 publications and holds 10 American and international patents. In 1997, he acquired the “NIH Inventor Award” and in 2004 the celebrated “NIH Advantage Award”.
Masitinib is a brand new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, essential cells for immunity, via inhibiting a restricted variety of kinases. Based mostly on its distinctive mechanism of motion, masitinib could be developed in a lot of situations in oncology, in inflammatory illnesses, and in sure illnesses of the central nervous system. In oncology because of its immunotherapy impact, masitinib can affect survival, alone or together with chemotherapy. By way of its exercise on mast cells and microglia and consequently the inhibition of the activation of the inflammatory course of, masitinib can affect the signs related to some inflammatory and central nervous system illnesses and the degeneration of those illnesses.
About AB Science
Based in 2001, AB Science is a pharmaceutical firm specializing within the analysis, growth and commercialization of protein kinase inhibitors (PKIs), a category of focused proteins whose motion are key in signaling pathways inside cells. Our packages goal solely illnesses with excessive unmet medical wants, typically deadly with quick time period survival or uncommon or refractory to earlier line of remedy.
AB Science has developed a proprietary portfolio of molecules and the Firm’s lead compound, masitinib, has already been registered for veterinary medication and is developed in human medication in oncology, neurological illnesses, and inflammatory illnesses. The corporate is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).
Additional info is offered on AB Science’s web site: www.ab-science.com.
Ahead-looking Statements – AB Science
This press launch comprises forward-looking statements. These statements should not historic info. These statements embrace projections and estimates in addition to the assumptions on which they’re based mostly, statements based mostly on tasks, aims, intentions and expectations concerning monetary outcomes, occasions, operations, future companies, product growth and their potential or future efficiency.
These forward-looking statements can typically be recognized by the phrases “count on”, “anticipate”, “consider”, “intend”, “estimate” or “plan” in addition to different related phrases. Whereas AB Science believes these forward-looking statements are affordable, buyers are cautioned that these forward-looking statements are topic to quite a few dangers and uncertainties which are troublesome to foretell and customarily past the management of AB Science and which can indicate that outcomes and precise occasions considerably differ from these expressed, induced or anticipated within the forward-looking info and statements. These dangers and uncertainties embrace the uncertainties associated to product growth of the Firm which might not be profitable or to the advertising authorizations granted by competent authorities or, extra typically, any components which will have an effect on advertising capability of the merchandise developed by AB Science, in addition to these developed or recognized within the public paperwork filed by AB Science with the Autorité des Marchés Financiers (AMF), together with these listed within the Chapter 4 “Danger Components” of AB Science reference doc filed with the AMF on November 22, 2016, underneath the quantity R. 16-078. AB Science disclaims any obligation or enterprise to replace the forward-looking info and statements, topic to the relevant laws, specifically articles 223-1 et seq. of the AMF Common Laws.
For extra info, please contact:
Monetary Communication & Media Relations